Kähäri, Veli-Matti

CIP2A inhibits PP2A in human malignancies

Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell

Cancer Mechanisms and TherapyProtein Tyrosine Phosphatases

Cited by 677

Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Laine, A., Sihto, H., Come, C., Rosenfeldt, M. T., Zwolinska, A., Niemelä, M., Khanna, A., Chan, E. K., Kähäri, V.-M., Kellokumpu-Lehtinen, P.-L., et al. (2013) · Cancer Discovery

Telomeres, Telomerase, and SenescenceCancer-related Molecular Pathways

Cited by 130

New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma

Nissinen, L., Farshchian, M., Riihilä, P., & Kähäri, V.-M. (2016) · Cell and Tissue Research

Nonmelanoma Skin Cancer StudiesSkin Protection and Aging

Cited by 80

Collagen Turnover in Wound Repair––A Macrophage Connection

Nissinen, L. M., & Kähäri, V.-M. (2015) · Journal of Investigative Dermatology

Wound Healing and TreatmentsProtease and Inhibitor Mechanisms

Cited by 37

Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias

Mäkelä, E., Pavic, K., Varila, T., Salmenniemi, U., Löyttyniemi, E., Nagelli, S. G., Ammunét, T., Kähäri, V.-M., Clark, R. E., Elo, L. L., et al. (2021) · Clinical Cancer Research

Chronic Myeloid Leukemia TreatmentsRNA Research and Splicing

Cited by 18